BridgeBio Pharma, Inc.

NASDAQ:BBIO

Biotechnology

Healthcare
$78.01 +1.13%

+$0.75 today

Market cap
$15.20B
Beta
0.97
P/E (TTM)
-18.1
EPS (TTM)
-$3.73
52W Low $40.19High $84.94

Volume 3.55M

Average 2.49M

BBIO Sales of Investments

Cash received from selling or redeeming investments.

BridgeBio Pharma, Inc.NASDAQ: BBIO

Sales of Investments · Q2 FY2026 · quarter ended Jun 2026

Sales of investments outflow grows to $29.6M

Q2 FY2026 sales of investments was $29.6M, compared with $0 a year earlier. Trailing-twelve-month sales of investments was $50.6M. Over 3 fiscal years it compounded at -72.6% a year.

Context

  • Sales of investments amounted to 2.2% of revenue in FY2025, down 69.1 pp from a year earlier.
  • Sales of investments increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly sales of investments holds near $29.6M or moves back toward the trailing-twelve-month quarterly average of $12.65M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$29.6M+196.0% QoQ
Last fiscal yearDec 2025
$11M-93.0% YoY
LTMJun 2026
$50.6M+26.5% YoY
Sales of Investments past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-93.0%——
3-year CAGR-72.6%——
5-year CAGR——
10-year CAGR——

Sales of Investments history

USD · from the cash flow

Latest · FY2025
11M USD
Year-over-year change
-93.0%
4-year CAGR
-61.0%

Sales of Investments vs competitors

How BBIO compares with its peers on the latest reported figures

  • Peers report in different currencies, so sales of investments is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +26.5% is the 4th highest of 10, against a peer median of -5.6%.
  • Sales of investments amounts to 7.1% of revenue for BBIO, versus a peer median of 103.6%.
BBIO Competitors
Sales of Investments for BBIO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BMRNBioMarin Pharmaceutical Inc.LTM Sep 2026$767.32B USD+170746.3%-18.3%74.7%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$1.82B USD+4.9%+19.7%189.3%
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$1.43B USD-16.9%-6.9%29.8%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$1.34B USD+87.1%+18.2%132.6%
DNLIDenali Therapeutics Inc.LTM Jun 2026$799.11M USD-8.5%-10.7%22172.9%
RAREUltragenyx Pharmaceutical Inc.LTM Mar 2026$395.01M USD-5.6%-6.6%59.0%
TVTXTravere Therapeutics, Inc.LTM Sep 2026$246.48M USD-16.8%-5.4%37.9%
SRRKScholar Rock Holding CorporationLTM Sep 2026$108.5M USD-63.0%+34.6%19035.1%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$50.6M USD+26.5%-72.6%7.1%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$47.5M USD——237.5%
ASNDAscendis Pharma A/SLTM Sep 2026€0 EUR+100.0%—0.0%
Peer median (excluding BBIO) —-5.6%-6.0%103.6%

Competitors are the stored peer set for BBIO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(586.45M)(484.65M)(643.2M)(543.35M)(724.93M)
Depreciation & Amortization5.84M6.77M6.49M6.08M5.43M
Deferred Income Tax(30.93M)0000
Stock-Based Compensation99.51M91.56M095.8M133.02M
Change in Working Capital(4.4M)28.08M5.06M32.04M(51.06M)
Accounts Receivables(19.75M)15.17M15.33M(2.97M)(134.72M)
Inventory19.75M000(25.31M)
Accounts Payables2.83M(349K)2.78M1.51M26.61M
Other Working Capital(7.23M)13.26M(13.05M)33.5M82.36M
Other Non-Cash Items18.5M(61.25M)103.93M(111.3M)191.63M
Operating Cash Flow(497.93M)(419.49M)(527.72M)(520.73M)(445.91M)
Capital Expenditures(48.25M)(6.32M)(1.31M)(933K)(1.1M)
Acquisitions (Net)(35M)00(140K)0
Purchases of Investments(643.28M)(193.06M)(137.26M)(88.4M)(28.2M)
Sales of Investments477.04M532.52M193.11M158.23M11M
Other Investing Activities48.65M118.5M(503K)(7.98M)(6.19M)
Investing Cash Flow(200.83M)453.15M54.03M60.78M(24.49M)
Debt Repayment1.08B(20.49M)0476.58M385.5M
Common Stock Issued04.85M449.81M314.74M34.15M
Common Stock Repurchased(204.75M)(1.56M)(6.88M)(7.53M)(48.28M)
Dividends Paid00000
Other Financing Activities(138.49M)4.06M8.61M(35.34M)(12.08M)
Financing Cash Flow736.45M(13.13M)451.54M748.46M359.29M
Effect of Forex Changes00000
Net Change in Cash37.69M20.52M(22.15M)288.51M(111.1M)
Free Cash Flow(546.18M)(425.82M)(529.03M)(521.66M)(447.01M)

BridgeBio Pharma, Inc.

NASDAQ:BBIO

Intrinsic Alpha fair value

Locked

Current Price

$78.01

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.